1 Endometrial Cancer Clinical Trials in New Hampshire

Endometrial Cancer clinical trials in New Hampshire

1 actively recruiting endometrial cancer trials at 1 site across New Hampshire.

Data from ClinicalTrials.gov · last refreshed 2026-06-15

Phase 3 Recruiting Industry

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment of progress…

Sponsor: AstraZeneca

NCT ID: NCT06989112

Sites in New Hampshire:

Research Site — Lebanon, New Hampshire

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-06-15